Life Sciences Tools and Services

AHWB

AHWB released FY2025 Annual Earnings on April 22, 2026 (BJT), with actual revenue of CNY 274.18 M and EPS of CNY 0.55

AHWB released FY2025 Q4 earnings on April 22, 2026 (BJT), actual revenue CNY 64.75 M, actual EPS CNY 0.0501

AHWB released FY2026 Q1 earnings on April 22 After-Market BJT, actual revenue CNY 30.54 M, actual EPS CNY -0.0039

AHWB FY2026 Q1 Earnings Release on April 23 After-Market (BJT)

AHWB to Release FY2025 Earnings Report on April 23, 2026 (BJT)

AHWB released FY2025 Q3 earnings on October 22 After-Market BJT, actual revenue CNY 62.59 M, actual EPS CNY 0.0975

AHWB released FY2025 9 Months Earnings on October 22 After-Market (BJT), actual revenue CNY 209.43 M, actual EPS CNY 0.4967

AHWB FY2025 Q3 Earning Release on October 23, 2025 After-Market (BJT)

AHWB released FY2025 Q2 earnings on August 25 After-Market (BJT), actual revenue CNY 75.79 M, actual EPS CNY 0.2192

AHWB released FY2025 Semi-Annual Earnings on August 25 After-Market (BJT), actual revenue CNY 146.84 M, actual EPS CNY 0.4

AHWB to Release FY2025 Semi-Annual Earnings on August 26, 2025 (BJT)

Investor Asks About Wanbang Medicine's Innovative Drug Business Progress

Wanbang Medicine's ESG Rating Dropped to CCC

Wanbang Medicine Cooperates with Jing San Bio on Eriochrome Acid Blue R

AHWB released FY2024 Q4 earnings on April 21 (BJT) with actual revenue of CNY 85.79 M and actual EPS of CNY 0.114

AHWB released FY2024 Annual Earnings on April 21, 2025 (BJT) with actual revenue of CNY 379.09 M and EPS of CNY 1.28

Wanbang Pharmaceutical Reports Revenue Growth But Declining Net Profits in 2024

Wanbang Pharmaceutical's Net Profit Down 60.09% in Q1 2025

AHWB released FY2025 Q1 earnings on April 21 After-Market (BJT), actual revenue CNY 71.05 M, actual EPS CNY 0.18

AHWB to Release FY2025 Q1 Earnings on April 22 After-Market BJT

301520

AHWB released its third-quarter report for 2025, with operating revenue of 209 million yuan in the first three quarters, a year-on-year decrease of 28.60%. The net profit attributable to the parent company was 33.1106 million yuan, a year-on-year decline of 57.44%; the net profit after deducting non-recurring gains and losses was 8.4492 million yuan, a year-on-year decrease of 84.89%. The basic earnings per share were 0.5 yuan

Zhitong

AHWB released its performance for the first three quarters, with a net profit attributable to the parent company of 33.1106 million yuan, a decrease of 57.44%

002550

000788

300584

300436

The innovative drug concept opened lower, with Cosunter down 10%, and Qianhong Bio-pharma, PKU HEALTHCARE, AHWB, Hicin Pharmaceutical, and Ruizhi Pharmaceutical all opening lower collectively

Qianhong Bio-pharma

PKU HEALTHCARE

Hicin Pharmaceutical

Cosunter

ChemPartner

The innovative drug concept fell at the beginning of the session, with Cosunter down 10%

301096

688222

301509

301230

The medical services sector has seen a short-term decline, with Kingchem dropping over 8%, followed by PR, Bio-S, HitGen, and AHWB

Bio-S

HitGen

Kingchem

The medical services sector has seen a short-term decline, with Kingchem falling over 8%

301371

603896

002243

Ergothioneine has recently attracted market attention, with several listed companies responding to related questions on interactive platforms. CITIC Securities' research report points out that ergothioneine has promising prospects in synthetic biology new materials. LEAGUER's equity investee, Ruidelin, has obtained Self-GRAS certification for ergothioneine; AHWB is collaborating with Sanofi on clinical projects; Shouxiangu's ergothioneine has natural antioxidant properties; Fuerjia's products contain ergothioneine ingredients

Fuerjia

Shouxiangu

LEAGUER

CITIC SEC

Ergothioneine receives attention, multiple listed companies respond to related questions

AHWB released its 2024 annual report, with operating revenue of 379 million yuan, a year-on-year increase of 10.91%. The net profit attributable to shareholders was 85.5307 million yuan, a year-on-year decrease of 20.87%; the net profit after deducting non-recurring gains and losses was 55.7878 million yuan, a year-on-year decrease of 42.90%. The basic earnings per share were 1.28 yuan

AHWB released its 2024 annual performance, with a net profit attributable to the parent company of 85.5307 million yuan, a decrease of 20.87%

AHWB released its Q1 2025 performance report, with operating revenue of 71.0522 million yuan, a year-on-year decrease of 21.20%; net profit attributable to the parent company of 11.8493 million yuan, a year-on-year decline of 60.09%; net profit after deducting non-recurring gains and losses of 5.3589 million yuan, a year-on-year decrease of 76.44%; basic earnings per share of 0.18 yuan

AHWB released its first-quarter performance, with a net profit attributable to the parent company of 11.8493 million yuan, a decrease of 60.09%

According to the Zhitong Finance APP, AHWB disclosed its profit distribution plan for the first three quarters of 2024, proposing a cash dividend of RMB 3.5 (tax included) for every 10 shares

AHWB plans to distribute a profit of 3.5 yuan for every 10 shares in the first three quarters

AHWB(301520.SZ)